Febbraio 2025: Novo Nordisk ha annunciato che il semaglutide 2.4 mg sarebbe stato disponibile nelle farmacie messicane entro aprile 2025, con una perdita di peso media del 17.5% osservata negli studi pivotali
Given the significant unmet need for novel therapeutic interventions in AS, particularly as many patients still progress to KF despite current treatments like RASi, GLP-1 RAs may offer an innovative strategy to delay KF in AS, potentially addressing both metabolic and inflammatory pathways involved in CKD progression [40, 42, 56]
While some peptides, such as insulin or GLP-1s like Ozempic, are legal and can be obtained with a doctor's prescription, most fall into a regulatory gray zone and can be sold only as "research" chemicals
Prescription Drug Benefits Announcement Looking for 2026 Open Enrollment information
Lahiri S, Kim H, Garcia-Perez I, Reza MM, Martin KA, Kundu P, et al